Roche's Neurology Portfolio Gains Momentum with Dual Regulatory Wins

Roche secures key U.S. billing code for Ocrevus Zunovo and FDA approval for oral Evrysdi tablet, while facing a manageable 15% tariff impact ahead of its Q1 2026 report.

The Swiss pharmaceutical giant Roche has solidified its position in the crucial U.S. market through recent regulatory successes and a manageable tariff outlook. These developments provide a stable foundation ahead of the company's first-quarter 2026 financial report, scheduled for release on April 23.

Streamlined Administration and Enhanced Patient Convenience

A significant milestone was achieved on April 1, 2025, with the establishment of a permanent J-Code (J2351) for Ocrevus Zunovo in the United States. This billing code is essential for securing reimbursement within the U.S. healthcare system and paves the way for broader commercial adoption. Ocrevus Zunovo is a subcutaneous formulation of ocrelizumab, a multiple sclerosis treatment first approved as an infusion in 2017. The new version enables administration via a single abdominal injection, a process taking roughly ten minutes, required only every six months.

In a parallel advancement for neurological care, the U.S. Food and Drug Administration (FDA) has approved a tablet form of Evrysdi (risdiplam) for spinal muscular atrophy (SMA). This authorization marks the world's first oral solid-dosage treatment for this rare neuromuscular condition. Evrysdi maintains its status as the sole non-invasive, disease-modifying therapy for SMA, now with the added practical benefit of room-temperature storage. This feature offers patients greater daily independence. The drug, available in over 100 countries, has already been used to treat more than 16,000 individuals globally.

Tariff Impact Less Severe Than Feared

While proposed U.S. import tariffs on pharmaceuticals remain a sector-wide concern, the specific impact on Roche appears contained. A proclamation from former President Trump on April 2 outlined potential duties of up to 100% on imported medicines. However, exports from Switzerland—which include products from Roche and its U.S. subsidiary Genentech—are subject to a lower rate of 15%. Roche's prior strategic commitment to invest USD 50 billion in American research and manufacturing capacity also positions the company to mitigate potential disruptions.

The upcoming Q1 sales figures on April 23 will offer initial insight into how Roche's U.S. operations are performing under these new trade conditions.

Financial Expectations for 2026

Market analysts project Roche's full-year 2026 revenue to reach an average of CHF 63.8 billion. This forecast represents a year-over-year increase of approximately 3.8%. The forthcoming quarterly report will indicate whether the recent neurology portfolio advancements are beginning to translate into measurable financial performance.